Navigation Links
TorreyPines Therapeutics Reports First Quarter 2008 Financial Results and Accomplishments

LA JOLLA, Calif., May 13 /PRNewswire/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) today reported its financial results and accomplishments for the first quarter ended March 31, 2008. For the three-month period, the company posted revenue of $2.0 million and a net loss of $3.9 million. Cash and cash equivalents totaled $25.7 million at March 31, 2008.

"We have been diligently executing on the strategic plan outlined in February, maximizing the value of our versatile compounds while prudently managing our resources," said Neil Kurtz, M.D., President and Chief Executive Officer of TorreyPines. "The role of glutamate in disease has been garnering much attention, further supporting the value of tezampanel and NGX426, our two ionotropic glutamate receptor antagonists. We are focused on developing better alternatives to current therapies and our pipeline reflects this effort, particularly as we move tezampanel toward the clinic in muscle spasticity and rigidity, our first non-pain indication for the drug, and with the recent initiation of a Phase II clinical trial evaluating NGX267 in xerostomia. Furthermore, the recent clinical guidance call held with the FDA supports the advancement of tezampanel in acute migraine."

First Quarter 2008 and Recent Accomplishments:

-- Held a clinical guidance teleconference with the U.S. Food and Drug

Administration (FDA) and confirmed that it has no objection to

TorreyPines moving forward into Phase III clinical trials for the

treatment of acute migraine with the 40 mg dose of tezampanel. Prior

to initiating any Phase III clinical trials, TorreyPines intends to

hold an end-of-Phase II meeting with the FDA, currently planned for

the second half of 2008, to discuss the overall Phase III program.

-- Completed a Phase I multiple dose clinical trial of tezampanel that

demonstrated the compound to be safe and well-tolerated, supporting the

development of tezampanel in pain and non-pain indications that require

chronic dosing.

-- Completed dosing of up to 210 mg of NGX426 in a Phase I maximum

tolerated dose trial evaluating the oral prodrug of tezampanel.

Following completion of this trial TorreyPines intends to initiate a

multiple dose clinical trial of NGX426 to support the chronic dosing of


-- Pharmacokinetic data from the ongoing Phase I maximum tolerated dose

trial of NGX426 suggest that 90 mg of NGX426 results in blood levels of

tezampanel that the company believes will prove to be analgesic.

TorreyPines intends to initiate a study in a model of capsaicin-induced

pain to confirm the analgesic activity of NGX426 administered orally,

with data from this study expected by the end of year.

-- Initiated a Phase II study of NGX267 for the treatment of xerostomia,

or dry mouth, secondary to Sjogren's syndrome. Data from this study

are expected by the end of year.

-- Presented animal data on TorreyPines' proprietary gamma secretase

modulator (GSM) compounds at the Keystone Symposium on Alzheimer's

disease. The data demonstrated that TorreyPines' GSM compounds provide

a more selective mechanism than gamma secretase inhibitors.

TorreyPines is developing its GSM compounds as a potential treatment

for Alzheimer's disease.

-- Acquired from Johns Hopkins University the rights to intellectual

property related to the novel use of glutamate receptor antagonists,

including TorreyPines' compounds tezampanel and NGX426, for the

prevention and treatment of stroke, heart attack and other conditions

associated with increased platelet aggregation.

-- Received notification that an abstract describing the results from the

completed Phase IIb clinical trial of tezampanel for the treatment of

acute migraine was accepted for presentation at the 50th Annual

Scientific Meeting of the American Headache Society to be held in

Boston June 26-29, 2008.

Financial Results

Revenue for the three month period ended March 31, 2008, was $2.0 million, compared to revenue of $2.5 million for the same period in 2007. Operating expenses for the quarter ended March 31, 2008, were $6.7 million, with $5.3 million attributable to research and development. This compares to operating expenses of $6.6 million and research and development expenses of $5.2 million for the same period last year. The company reported a net loss for the quarter ended March 31, 2008, of $3.9 million compared to a net loss of $3.3 million for the previous year.

Conference Call/Webcast Information

TorreyPines will host a conference call and Webcast at 11 a.m. EDT today. The audio Webcast can be accessed at To participate in this call, dial 719-325-4817 and enter the passcode 2644321. For a limited period following the call, a replay will be available beginning at 2 p.m. EDT. The replay can be accessed by calling 719-457-0820 and entering passcode 2644321.

About TorreyPines Therapeutics

TorreyPines Therapeutics, Inc. is a biopharmaceutical company committed to providing patients with better alternatives to existing therapies through the research, development and commercialization of small molecule compounds. The company's goal is to develop versatile product candidates each capable of treating a number of acute and chronic diseases and disorders such as migraine, chronic pain, muscle spasticity and rigidity, xerostomia and cognitive disorders. The company is currently developing four product candidates: two ionotropic glutamate receptor antagonists and two muscarinic receptor agonists. Further information is available at

This press release contains forward-looking statements or predictions. Such forward-looking statements include, but are not limited to, statements regarding the plans for holding an end of Phase II meeting with the FDA, anticipated timing for initiating a Phase II clinical trial of tezampanel for treatment of muscle spasticity and rigidity, anticipated timing for initiating a multiple dose clinical trial of NGX426, the potential for tezampanel and NGX426 as treatments for acute migraine and other indications, the potential for NGX426 to be analgesic, the anticipated timing of results for the NGX426 study in a model of capsaicin-induced pain, the plans for expanding the clinical profile of tezampanel, the potential for NGX267 as a treatment for xerostomia, the anticipated timing of results from the study of NGX267 as a treatment for xerostomia, the potential for the gamma secretase modulator compounds to treat Alzheimer's disease and the potential for NGX426 to treat stroke, heart attack and other conditions associated with increased platelet aggregation. Such statements are subject to numerous known and unknown risks, uncertainties and other factors, which may cause TorreyPines' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements, including whether any preclinical studies or clinical trials, either ongoing or conducted in the future, will prove successful, and if successful, whether the results can be replicated; whether safety and efficacy profiles of any of the company's product candidates will be established, or if established, will remain the same, be better or worse in future clinical trials, if any; whether pre-clinical results will be substantiated by ongoing or future clinical trials, if any, or whether any of the company's product candidates will be able to improve the signs or symptoms of their respective clinical indication; whether any of the company's product candidates will support a filing for marketing approval, will be approved by the regulatory authorities, or if approved, will prove competitive in the market; or whether the necessary financing to support the company's product development programs will be available. In particular there is no guarantee that clinical trials of any of the company's product candidates will be completed on schedule or that results of these clinical trials will be reported within the anticipated timeframe, that tezampanel or NGX426 will successfully treat migraine and/or other indications for which they are developed, that the End of Phase II meeting will be held in the anticipated time frame, that NGX267 will successfully treat xerostomia secondary to Sjogren's syndrome, that the company's gamma secretase modulators will be able to successfully treat Alzheimer's disease or that TorreyPines will be able to complete the necessary development work and receive regulatory approval for tezampanel, NGX426 or NGX267. These and other risks which may cause results to differ are described in greater detail in the "Risk Factors" section of TorreyPines' annual report on Form 10-K for the year ended December 31, 2007 and TorreyPines other SEC reports. The forward-looking statements are based on current information that is likely to change and speak only as of the date hereof.

Company Contact: Media Contact:

Craig Johnson David Schull

TorreyPines Therapeutics, Inc. Russo Partners, LLC

858-623-5665, x158 212-845-4271

Investor Contact:

Rhonda Chiger

Rx Communications


(Tables Follow)

TorreyPines Therapeutics, Inc.

Condensed Consolidated Balance Sheets

(in thousands)

March 31, December 31,

2008 2007



Current assets

Cash and cash equivalents $ 25,665 $ 32,500

Prepaid expenses and other current assets 543 835

Total current assets 26,208 33,335

Long-term assets 5,846 5,317

Total assets $ 32,054 $ 38,652

Liabilities and stockholders' equity

Current liabilities $ 8,142 $ 9,036

Debt and other long-term liabilities 47 973

Deferred revenue 900 2,183

Total liabilities 9,089 12,192

Total stockholders' equity 22,965 26,460

Total liabilities and stockholders' equity $ 32,054 $ 38,652

TorreyPines Therapeutics, Inc.

Condensed Consolidated Statements of Operations

(in thousands, except per share amounts)


Three months ended

March 31,

2008 2007

Revenue $ 2,046 $ 2,463

Operating expenses:

Research and development 5,260 5,177

General and administrative 1,448 1,395

Total operating expenses 6,708 6,572

Loss from operations (4,662) (4,109)

Other income (expense)

Interest income 217 608

Interest expense (147) (238)

Other income (expense), net 699 458

Total other income 769 828

Net loss $ (3,893) $ (3,281)

Basic and diluted net loss per share $ (0.25) $ (0.21)

Weighted average shares used in the

computation of basic and diluted net loss

per share 15,739,646 15,688,079

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. TorreyPines Therapeutics to Present at the JMP Securities Healthcare Focus Conference
2. TorreyPines Therapeutics to Present at BMO Capital Markets Focus on Healthcare Conference
3. Gamma Secretase Modulators Show Promise in Alzheimers Disease Animal Model Efficacy Studies, According to Research Conducted by TorreyPines Therapeutics
4. TorreyPines Therapeutics Licenses Intellectual Property from Johns Hopkins Related to Novel Uses of Glutamate Receptor Antagonists for Prevention, Treatment of Stroke, Heart Attack
5. Prime Therapeutics Receives TIPPS Certification
6. Adams Respiratory Therapeutics to Celebrate 10th Anniversary of its Incorporation on September 12
7. Transition Therapeutics Announces Fiscal 2007 Year End Financial Results
8. Lorus Therapeutics announces election of three new Directors and appoints a new Chairman
9. Deane F. Johnson Center for Neurotherapeutics to Launch First Mobile Medical Unit on October 4th
10. Russell Investment Group Advises Protalix Biotherapeutics of Index Adjustment
11. Adams Respiratory Therapeutics Announces FDA Approval of Grape-Flavored Delsym(R)
Post Your Comments:
(Date:11/29/2015)... , ... November 29, 2015 , ... While conventional walkers ... or provide ready access to exercise weights. Fortunately, an inventor from Uniontown, Pa., has ... TOMMY WALKER to enhance the benefits of a standard walker to improve the user’s ...
(Date:11/28/2015)... ... November 28, 2015 , ... ... and teleradiology services, has added Chris Hafey and Claude Hooton to its board ... Radiological Society of North America (RSNA) 2015 Annual Meeting and continues to strategically ...
(Date:11/27/2015)... , ... November 28, 2015 , ... There is only ... outperform our billings from last year? , This question has not been an easy ... coming to the retirement age and the younger workforce don’t share the same discipline ...
(Date:11/27/2015)... Raleigh, NC (PRWEB) , ... November 27, 2015 , ... ... most effective ways to treat it. Surviving Mesothelioma has just posted the findings ... Researchers at University Hospital Zurich analyzed the cases of 136 mesothelioma patients who were ...
(Date:11/27/2015)... Aliso Viejo, CA (PRWEB) , ... November 27, 2015 , ... ... exclusively for use in Final Cut Pro X. With ProSidebar: Fasion, video editors ... banners, or use ProSidebar as a minimalist title opener. Utilize presets featuring self-animating ...
Breaking Medicine News(10 mins):
(Date:11/29/2015)... Germany , Nov. 29, 2015  At this ... attendees to experience the most complete mobile C-arm portfolio ... display is Ziehm Vision RFD 3D, the world,s only ... cm edge length per scan volume. In addition, Ziehm ... fully motorized mobile C-arm in four axes which is ...
(Date:11/29/2015)... 2015 CIVCO Medical Solutions will demonstrate ... Radiological Society of North America ... November 29 – December 4, 2015. The ... customers unrivaled versatility, enhanced user experience and deliver ... --> --> ...
(Date:11/27/2015)... Pays-Bas, November 27, 2015 ... traitement photodynamique au Bremachlorin contre le cancer avancé. ... consistant à combiner l,immunothérapie au traitement photodynamique au ... --> Une nouvelle approche consistant à ... le cancer avancé.    Clinical ...
Breaking Medicine Technology: